An observational study in Stage II Colon Cancer and Stage III Colon Cancer, sponsored by Boryung Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Boryung Pharmaceutical Co., Ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Colonic Neoplasms with a site in Korea, Republic of — 13 open to participants now, 29 under way, 10 of them phase 3. Colonic Neoplasms · Korea, Republic of.
Among the 82 studies in Colonic Neoplasms with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 15 observational ones that give a count, is one of 6 that started in 2020, is one of 15 observational ones, reaches primary completion later than 16 of the 28 other live ones, and was the 52nd registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
Browse Colonic Neoplasms studies →13 of the 82 studies in Colonic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
hy Co., LTD. · Sites in Korea, Republic of
Ages 20–80
Incyte Corporation · Sites in Korea, Republic of, United States, Argentina and 19 more countries
Ages 18+
Pheon Therapeutics · Sites in Korea, Republic of, United States, Spain
Ages 18+
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Argentina and 26 more countries
Ages 18+
Ulsan University Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 22 · Phase 3 14 · Phase 4 2
First in 1991; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,013 is above the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Median enrollment 174 across the 65 interventional studies, 300 across the 15 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
Boryung Pharmaceutical Co., Ltd has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Colonic Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04416490Boryung Pharmaceutical Co., LtdOxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer | 2027-02 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT07127874Pheon TherapeuticsA Study of PHN-012 in Patients With Advanced Solid Tumors | 2027-09 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 82 studies in Colonic Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to general medical guidelines, adjuvant chemotherapy is used after curative resection of high-risk stage II or III primary colon cancer. However, there exist limitations using clinical trial data acquired from highly selected subjects in a controlled environment. For example, patients aged over 70 years old were in many cases excluded from clinical trials resulting in insufficient data on the efficacy of therapies including oxaliplatin in aged patients, and the source data of the medical guidelines did not fully reflect the conditions of Korean patients. In addition, suggestions are continuously being submitted for existing therapies with modified administration periods and methods with the aim to search for the optimum effect over side effects. Discussions are also held on meta analyses results that imply the need to apply slightly different approaches through small groups of patient and disease factors. As there are more diverse adjuvant therapy protocols that can be applied to post-surgery colon cancer patients, it is necessary to figure out the patterns of adjuvant chemotherapies actually used in Korean medical practices. Also, in order to complement the limitation of external validity of the existing base clinical data, a multifaceted exploratory analysis will be conducted by making follow-up observations on patterns, prognosis results, quality of life, adverse effects, etc. of post-surgery adjuvant chemotherapies actually used in around 30 sites in Korea under the noninterventional observational study conditions.
[Overview] Investigators will obtain voluntary consent for participation in this study from patients with high-risk stage II or stage III colon cancer who require or are planning to receive adjuvant chemotherapy after curative resection. Patients who provided written consent for using their personal information and who satisfy inclusion/exclusion criteria will be given a study enrollment number. Among the predefined study-relevant data, available data on these patients will be collected in the case report forms (CRF) until the study is completed.
[Follow-up observation schedule and the scope of data collection] Since this study is an observational study, data collection in the CRF will be restricted to the data created only from usual treatment practices and there will be no separate test or additional drug administration for the study. However, subjects will be asked to complete questionnaire to evaluate their quality of life at the following time points: baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks). For subjects who drop out from the study or in case of disease event (relapse, metastasis or new primary malignant tumor), the questionnaire will be conducted at the time of drop-out or disease event. Survival of all subjects (including those who drop out from the study or whose disease event is confirmed) will be checked every 6 months after adjuvant chemotherapy started. Among the data created from the subjects on their visits for treatment, the following data will be collected for the purpose of this study.
Patients with high-risk stage II or stage III primary colon cancer who have received curative resection. Approximately 2,000 subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are confirmed to have primary colon cancer through histological diagnosis and are at *high-risk stage II (T3/4, N0M0) or stage III (any T, N1/2, M0).
High-risk stage II is determined when one or more of the following are applicable.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with high-risk stage II or stage III primary colon cancer who have received curative resection
Type of adjuvant chemotherapy
Type of adjuvant chemotherapy that were used.
Time frame: through adjuvant chemotherapies completion, an average of 24 weeks
Frequency of adjuvant chemotherapy
Frequency of adjuvant chemotherapy that were used.
Time frame: through adjuvant chemotherapies completion, an average of 12 cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days)
Disease Free Survival (DFS)
Time from the date of resection surgery to the date of first relapse,
Time frame: From date of resection surgery until the date of first documented progression, assessed up to 36 months
Overall Survival (OS)
Time from the date of resection surgery to the date of death.
Time frame: From date of resection surgery until the date of death, assessed up to 36 months
Characteristics of relapsed and metastasis cancers and new primary malignant tumor list.
Whether locally relapsed, whether metastasis is present, location of metastasis, etc.
Time frame: up to 36 months
Quality of Life Assessment (FACT-C)
Subjects will be asked to complete questionnaires to evaluate their quality of life
Time frame: Baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Quality of Life Assessment (FACT/GOG-NTX-12)
Subjects will be asked to complete questionnaires to evaluate their quality of life
Time frame: Baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Adverse drug reactions/serious adverse drug reactions
Overall incidence of grade 3-4 adverse drug reactions/serious adverse drug reactions
Time frame: From the date of adjuvant chemotherapy started until the end of follow-up(36 month)
Oxaliplatin Induced Peripheral Neuropathy, OXLIPN
Overall incidence of Oxaliplatin Induced Peripheral Neuropathy, OXLIPN
Time frame: From the date of adjuvant chemotherapy started until the end of follow-up(36 month)
Performance Status (ECOG) evaluation results
Frequency and ratio of ECOG evaluation results will be presented by time point.
Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Results on weight
Descriptive statistics will be presented for the results of weight by time point.
Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Results on body temperature
Descriptive statistics will be presented for the results of body temperature by time point.
Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Results on pulse
Descriptive statistics will be presented for the results of pulse by time point.
Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Results on blood pressure
Descriptive statistics will be presented for the results of blood pressure by time point.
Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)
Started Mar 2020 (actual). Primary completion is estimated for Feb 2027, 83 months after the start.
Of 225 observational studies under Colonic Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 83 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd →